TCT 2019 | EVOLVE Short DAPT: Only 3-month DATP in High Risk Bleeding

Courtesy of the SBHCI.

This study used the thin strut everolimus eluting stent with ultrathin abluminal bioresorbable polymer coating chromium platinum stent, basically the Synergy stent. Drug release and polymer degradation within four months facilitate endothelization and would allow a shorter DAPT.

Highlights TCT 2019

Presented during the scientific sessions of TCT 2019, this study included 2009 high risk bleeding patients (>75 high risk of bleeding, use of oral anticoagulation, major bleeding in the last year with a history of stroke, thrombocytopenia or kidney failure).

After PCI, patients received DAPT (aspirin + P2Y12 inhibitor) for 3 months, except in anticoagulated patients where aspirin was optional. 


Read also: TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS.


Patients who did not present clinical events and had discontinued the P2Y12 inhibitor at month 3, continued with aspirin up to 3 to 15 months. 

Primary end point was death or infarction between month 3 and 15 after procedure compared against a historical cohort receiving the classic 12-month DAPT. Events rate in patients receiving 3-month DAPT was 5.6% vs 5.7% for the historical cohort (p for non-inferiority = 0.0016). Thrombosis rate was 0.3% for an expected 1%.

Total bleeding and major bleeding rates resulted similar between the groups. (6.26% vs 4.1%).

Courtesy of the SBHCI.

Link to the SBHCI publication HERE

evolve_short_dapt_2-1

Original Title: EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent.

Reference: Jamil Cade.

Author of the Original Article: Ajay J. Kirtane.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...